VRTX price target
Vertex Pharmaceuticals Incorporated · end-of-day data as of Oct 16, 2026
Vertex Pharmaceuticals Incorporated
$499.74+4.7%
Buy · 33 analystsPT $569.95 +14.0%
The average price target of the 18 analyst firms that published one in the last 12 months is $569.95 for VRTX, 14.0% above the last close of $499.74 on Oct 16, 2026. Targets range from $345.15 to $665.00, with a median of $587.41. Rating consensus: Buy.
Summary
- Target upside+14.0%
- ConsensusBuy
Analyst price targets
Low$345.15
Average$569.95
Median$587.41
High$665.00
Upside+14.0%
18 firms with a target in the last 12 months · last close $499.74 · as of Oct 16, 2026
Barclays$4102025-11-04
Cantor Fitzgerald$4792025-11-04
RBC Capital$4102025-11-04
Stifel Nicolaus$4402025-11-04
Jefferies$5832026-03-10
Truist Financial$5252026-03-10
BMO Capital$5982026-03-02
Barclays$5902026-02-17
H.C. Wainwright$5742026-02-17
Bernstein$5702026-02-13
+14 more
Canaccord Genuity$4282026-02-17
Truist Financial$5442026-05-27
Barclays$6202026-05-06
Bernstein$5652026-05-05
Morgan Stanley$6262026-05-05
RBC Capital$5362026-05-05
Morgan Stanley$6112026-04-10
Canaccord Genuity$4302026-05-05
Canaccord Genuity$4412026-04-30
Goldman Sachs$6572026-09-01
Morgan Stanley$6652026-09-01
Bernstein$6072026-08-11
Wolfe Research$5632026-08-10
Barclays$6252026-08-05
Truist Financial$5612026-08-05
+5 more
Robert W. Baird$3452026-07-07
Canaccord Genuity$4502026-08-04
RBC Capital$5772026-10-08
UBS$6152026-09-28
Jefferies$6422026-09-23
H.C. Wainwright$6352026-09-22
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
Strong buy 6 · Buy 20 · Hold 5 · Sell 1 · Strong sell 1